|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
18
|
|
pubmed:dateCreated |
2011-6-20
|
|
pubmed:abstractText |
Clinicians are increasingly willing to treat prostate cancer within the primary site in the presence of regional lymph node or even limited distant metastases. However, no formal study on the merits of this approach has been reported. We used a preoperative clinical discovery platform to prioritize pathways for assessment as therapeutic targets and to test the hypothesis that the primary site harbors potentially lethal tumors after aggressive treatment.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2574-81
|
|
pubmed:meshHeading |
pubmed-meshheading:21606419-Adenocarcinoma,
pubmed-meshheading:21606419-Adult,
pubmed-meshheading:21606419-Aged,
pubmed-meshheading:21606419-Androgens,
pubmed-meshheading:21606419-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:21606419-Cell Adhesion Molecules,
pubmed-meshheading:21606419-Combined Modality Therapy,
pubmed-meshheading:21606419-Cystectomy,
pubmed-meshheading:21606419-Disease Progression,
pubmed-meshheading:21606419-Gene Expression Profiling,
pubmed-meshheading:21606419-Humans,
pubmed-meshheading:21606419-Lymphatic Metastasis,
pubmed-meshheading:21606419-Male,
pubmed-meshheading:21606419-Middle Aged,
pubmed-meshheading:21606419-Neoadjuvant Therapy,
pubmed-meshheading:21606419-Neoplasm Proteins,
pubmed-meshheading:21606419-Neoplasms, Hormone-Dependent,
pubmed-meshheading:21606419-Neoplastic Stem Cells,
pubmed-meshheading:21606419-Neovascularization, Physiologic,
pubmed-meshheading:21606419-Prospective Studies,
pubmed-meshheading:21606419-Prostatectomy,
pubmed-meshheading:21606419-Prostatic Neoplasms,
pubmed-meshheading:21606419-Signal Transduction,
pubmed-meshheading:21606419-Taxoids,
pubmed-meshheading:21606419-Time Factors,
pubmed-meshheading:21606419-Tumor Markers, Biological
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.
|
|
pubmed:affiliation |
The University of Texas MD Anderson Cancer Center, 1155 Pressler St, Houston, TX 77030-3721, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
